Interactive effects of systemic inflammation and life stressors on treatment response of depressive disorders

被引:2
作者
Choi, Wonsuk [1 ]
Stewart, Robert [2 ,3 ]
Kang, Hee-Ju [4 ]
Kim, Ju-Wan [4 ]
Kim, Hee Kyung [1 ]
Kang, Ho-Cheol [1 ]
Lee, Ju-Yeon [4 ]
Kim, Sung-Wan [4 ]
Kim, Jae-Min [4 ]
机构
[1] Chonnam Natl Univ, Med Sch, Chonnam Natl Univ Hwasun Hosp, Dept Internal Med, Hwasun, South Korea
[2] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England
[3] South London & Maudsley NHS Fdn Trust, London, England
[4] Chonnam Natl Univ, Med Sch, Dept Psychiat, Gwangju, South Korea
基金
新加坡国家研究基金会;
关键词
Depression; Remission; Inflammation; Life stressors; Antidepressant; C-REACTIVE PROTEIN; SIGNAL-TRANSDUCTION THEORY; 2016 CLINICAL GUIDELINES; TREATMENT OUTCOMES; MAJOR DEPRESSION; CANADIAN NETWORK; EVENTS; INTERLEUKIN-6; ANTIDEPRESSANTS; ANXIETY;
D O I
10.1016/j.bbi.2021.01.029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inflammation is an important contributor in the pathophysiology of depression and recent evidence suggests that systemic inflammation and life stressors have interactive roles in depression onset. The aim of the present study was to investigate the individual and interactive effects of systemic inflammation and life stressors with shortand long-term treatment responses in outpatients with depressive disorders in a naturalistic one-year prospective design. Serum high-sensitivity C-reactive protein (hsCRP) levels were measured and number of stressful life events (SLEs) during the last 3 months were ascertained from 1094 patients at baseline. These patients received initial antidepressant monotherapy, then, for patients with an insufficient response or uncomfortable side effects, next treatment with alternative strategies were administered at every 3 weeks in the acute treatment phase (3, 6, 9, and 12 weeks) and at every 3 months in the continuation treatment phase (6, 9, and 12 months). 12-week and 12month remission was estimated, defined as a Hamilton Depression Rating Scale score of <= 7. In multivariable logistic regression analyses, individual effects were found only between higher baseline serum hsCRP levels (>1.0 vs. < 1.0 mg/L) and 12-week non-remission. Significant interactive effects between higher hsCRP levels and higher number of SLEs (>2 vs. < 2) on both 12-week and 12-month non-remission were observed. Combining serum hsCRP levels and number of SLEs might therefore be a useful predictor for short- and longterm treatment responses in patients with depressive disorders receiving pharmacotherapy.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 50 条
  • [1] Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
    Anderson, I. M.
    Ferrier, I. N.
    Baldwin, R. C.
    Cowen, P. J.
    Howard, L.
    Lewis, G.
    Matthews, K.
    McAllister-Williams, R. H.
    Peveler, R. C.
    Scott, J.
    Tylee, A.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2008, 22 (04) : 343 - 396
  • [2] DO PSYCHOSOCIAL FACTORS INFLUENCE OUTCOME IN SEVERELY DEPRESSED FEMALE PSYCHIATRIC-INPATIENTS
    ANDREW, B
    HAWTON, K
    FAGG, J
    WESTBROOK, D
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 : 747 - 754
  • [3] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders
    Bauer, Michael
    Pfennig, Andrea
    Severus, Emanuel
    Whybrow, Peter C.
    Angst, Jules
    Moeller, Hans-Juergen
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2013, 14 (05) : 334 - 385
  • [4] Predicting the short-term outcome of first episodes and recurrences of clinical depression: A prospective study of life events, difficulties, and social support networks
    Brugha, TS
    Bebbington, PE
    Stretch, DD
    MacCarthy, B
    Wykes, T
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (07) : 298 - 306
  • [5] The role of immune genes in the association between depression and inflammation: A review of recent clinical studies
    Bufalino, Chiara
    Hepgul, Nilay
    Aguglia, Eugenio
    Pariante, Carmine M.
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2013, 31 : 31 - 47
  • [6] Treatment response and cognitive impairment in major depression: Association with C-reactive protein
    Chang, Hui Hua
    Lee, I. Hui
    Gean, Po Wu
    Lee, Sheng-Yu
    Chi, Mei Hung
    Yang, Yen Kuang
    Lu, Ru-Band
    Chen, Po See
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2012, 26 (01) : 90 - 95
  • [7] Cumulative Depression Episodes Predict Later C-Reactive Protein Levels: A Prospective Analysis
    Copeland, William E.
    Shanahan, Lilly
    Worthman, Carol
    Angold, Adrian
    Costello, E. Jane
    [J]. BIOLOGICAL PSYCHIATRY, 2012, 71 (01) : 15 - 21
  • [8] Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder
    Eller, Triin
    Vasar, Veiko
    Shlik, Jakov
    Maron, Eduard
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (02) : 445 - 450
  • [9] Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue
    Enache, Daniela
    Pariante, Carmine M.
    Mondelli, Valeria
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2019, 81 : 24 - 40
  • [10] Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression
    Gupta, Rachna
    Gupta, Keshav
    Tripathi, A. K.
    Bhatia, M. S.
    Gupta, Lalit K.
    [J]. PHARMACOLOGY, 2016, 97 (3-4) : 184 - 188